GTx Closer To Filing NDA For Acapodene With Promising Phase III Results
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Reduced vertebral fracture risk means the selective androgen receptor modulator could offer median survival improvement
You may also be interested in...
GTx Files Toremifene For Prostate Cancer-Related Bone Loss
GTx is looking to be first to market with a treatment for prostate cancer patients that helps prevent common and debilitating fractures caused by androgen deprivation therapy.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Over The Counter 2 Apr 2024: Analyzing The Spin-Out Trend In Consumer Health, With HBW’s Malcolm Spicer And Tom Gallen
In this episode, HBW Insight’s Europe and US editors bring their expertise to bear on the current the trend towards standalone OTC companies in global consumer health. We look at four major players: Haleon, which separated from GSK almost two years ago; Kenvue, soon to celebrate its first anniversary as a new company; Sanofi Consumer Healthcare, which is poised to split from its pharma parent; and Bayer, which has decided to buck the trend, holding on to its consumer health division. We discuss some of the advantages of becoming a standalone company, for example in leaning into a wider concept of self-care.